Susan Oakley, MD
Urogynecology and Reconstructive Pelvic Surgery · Edgewood, KYNPI 1982894721
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,575 of the $23,239 with a category attached, or 75.6%. Medtronic accounts for 91.9% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $5,951 and has fallen 82.0% since, to $1,071 in 2025.
Across 229 payments — averaging $101.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$21K
- AbbVie$645
- Astellas Pharma US Inc$466
- Pfizer$255
- Coloplast$86
- Therapeuticsmd, Inc.$77
- plus $350 from 11 others
Across 19 payments — averaging $3825.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$73K
What the payments were for
- Speaking & faculty fees$17,57576%
- Travel & lodging$1,3416%
- Food & beverage$4,15918%
- Education$1641%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 111 | $21,360 |
| AbbVie(2 entities) | 41 | $645 |
| Astellas Pharma US Inc | 25 | $466 |
| Pfizer | 18 | $255 |
| Coloplast | 5 | $86 |
| Therapeuticsmd, Inc. | 5 | $77 |
| Duchesnay USA Incorporated | 5 | $76 |
| Lupin Inc. | 3 | $47 |
| Ferring Pharmaceuticals Inc. | 3 | $44 |
| AMAG Pharmaceuticals, Inc. | 3 | $39 |
| Urovant Sciences Inc | 2 | $36 |
| Sumitomo Pharma America, Inc. | 2 | $31 |
| Boston Scientific | 2 | $26 |
| Pacira Pharmaceuticals Incorporated | 1 | $15 |
| Axonics, Inc. | 1 | $13 |
| Avion Pharmaceuticals | 1 | $12 |
| Intuitive Surgical | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few urogynecology and reconstructive pelvic surgery providers in Kentuckyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 172 | $116,377 |
| MyrbetriqMirabegron | 156 | $104,865 |
| LinzessLinaclotide | 25 | $17,681 |
| PremarinEstrogens, Conjugated | 32 | $14,332 |
| Mirabegron ErMirabegron | 18 | $8,094 |
| Oxybutynin Chloride ErOxybutynin Chloride | 356 | $6,792 |
| Estradiol | 112 | $6,395 |
| Trospium Chloride | 47 | $2,414 |
| Solifenacin Succinate | 19 | $688 |
| Estradiol (Once Weekly)Estradiol | 11 | $435 |
| Oxycodone Hcl | 133 | $296 |
| Cephalexin | 77 | $253 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 29 | $247 |
| Clobetasol Propionate | 13 | $245 |
| Clindamycin Hcl | 14 | $128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $31 | $116,377172 claims |
| Astellas Pharma US IncMyrbetriq | $466 | $104,865156 claims |
| AbbVieLinzess | $645 | $17,68125 claims |
| PfizerPremarin | $255 | $14,33232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in Kentuckyon file to place this against a meaningful peer group, so we don't.
Other urogynecology and reconstructive pelvic surgery in Edgewood
- Caroline Elmer-LyonEdgewood$7K
- Parisa SamimiBowling Green$9K
- Shubham GuptaLexington$8K
- Sarah KaneLouisville$5K
- Gerardo Heredia MeleroLexington$4K
- Jenna WarehimeLouisville$4K
- Majorie PilkintonLouisville$3K
- Susan TateLouisville$2K
- Andrew DoeringLouisville$2K
- Kurt JaenickeLouisa$134
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.